Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patients
Charlotte Evans(University of Leeds), Talha Munir(Leeds Teaching Hospitals NHS Trust), Sue Bell(University of Leeds), Anita Sarma(Leeds Teaching Hospitals NHS Trust), Adrian Bloor(The Christie NHS Foundation Trust), David Allsup(University of Leeds), Darren Newton(University of Leeds), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Sharon Jackson(University of Leeds), Anna Hockaday(University of Leeds), Abraham Varghese(Leeds Teaching Hospitals NHS Trust), Nichola Webster(University of Leeds), Ruth de Tute(Leeds Teaching Hospitals NHS Trust), Surita Dalal(University of Leeds), Jennifer Carter(Leeds Teaching Hospitals NHS Trust), Andy C. Rawstron(St James's University Hospital), David Stones(University of Leeds), Natasha Greatorex(University of Leeds)
Cited by 2
Related Papers
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k